Company intelligence / Profile preview

Vivo Capital

Palo Alto, California, United Statesvivocapital.com ↗

Ownership: Private
Development stage: Other

Overview

Vivo Capital manages over $5.3 billion in assets and has invested in more than 430 public and private healthcare/life sciences companies globally since its founding in 1996. Its funds have supported the development of multiple FDA-approved therapies via investments in biotechs such as Verona Pharma ("Ohtuvayre" for COPD), Geron Corporation ("Rytelo" for myelodysplastic syndrome), Avadel Pharmaceuticals ("Lumryz" for narcolepsy), Soleno Therapeutics ("Vykat XR" for Prader-Willi Syndrome) among others. Several portfolio companies have been acquired by major pharmaceutical firms following clinical or commercial success.

Therapeutic areas: Other
Modalities: not applicable — invests across all modalities
Industry: Investors

Partnerships

Global institutional LP base/co-investors

Beyond the preview

Go deeper on Vivo Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivo Capital.

Explore the full profile